

Peter Lachmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8545392/publications.pdf>

Version: 2024-02-01

134
papers

8,553
citations

47006

47
h-index

48315

88
g-index

137
all docs

137
docs citations

137
times ranked

5530
citing authors

#	ARTICLE	IF	CITATIONS
1	CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.. Journal of Experimental Medicine, 1989, 170, 637-654.	8.5	618
2	Systemic Lupus Erythematosus, Complement Deficiency, and Apoptosis. Advances in Immunology, 2001, 76, 227-324.	2.2	461
3	Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology, 1990, 71, 1-9.	4.4	419
4	Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. Journal of Immunology, 1985, 134, 3307-15.	0.8	344
5	REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS. Journal of Experimental Medicine, 1970, 131, 643-657.	8.5	263
6	THE LOCALIZATION OF IN VIVO BOUND COMPLEMENT IN TISSUE SECTIONS. Journal of Experimental Medicine, 1962, 115, 63-82.	8.5	255
7	The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clinical and Experimental Immunology, 2008, 99, 160-167.	2.6	240
8	Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. Journal of Virology, 1994, 68, 8001-8007.	3.4	239
9	Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. Journal of Immunology, 1985, 135, 2005-14.	0.8	229
10	Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.. Journal of Clinical Investigation, 1996, 98, 2819-2826.	8.2	227
11	Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.. Journal of Experimental Medicine, 1982, 156, 205-216.	8.5	214
12	REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS. Journal of Experimental Medicine, 1970, 131, 629-641.	8.5	200
13	The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clinical and Experimental Immunology, 2008, 84, 1-8.	2.6	191
14	The Amplification Loop of the Complement Pathways. Advances in Immunology, 2009, 104, 115-149.	2.2	187
15	Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure, 1994, 2, 185-199.	3.3	178
16	The demonstration in human serum of "conglutinin-activating factor" and its effect on the third component of complement. Journal of Immunology, 1968, 100, 691-8.	0.8	163
17	Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2018, 391, 1108-1120.	13.7	153
18	Membrane defence against complement lysis: The structure and biological properties of CD59. Immunologic Research, 1993, 12, 258-75.	2.9	151

#	ARTICLE	IF	CITATIONS
19	The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. <i>Clinical and Experimental Immunology</i> , 1996, 106, 243-252.	2.6	138
20	The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). <i>Immunology</i> , 1973, 24, 259-75.	4.4	136
21	Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. <i>Clinical and Experimental Immunology</i> , 1985, 59, 547-54.	2.6	130
22	Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). <i>European Journal of Immunology</i> , 1984, 14, 236-243.	2.9	119
23	Complement-mediated adipocyte lysis by nephritic factor sera.. <i>Journal of Experimental Medicine</i> , 1993, 177, 1827-1831.	8.5	119
24	The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. <i>Clinical and Experimental Immunology</i> , 1975, 21, 109-14.	2.6	112
25	Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. <i>Immunology</i> , 2001, 103, 390-398.	4.4	106
26	Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. <i>Clinical and Experimental Immunology</i> , 1997, 108, 220-226.	2.6	104
27	Identification of Ss protein as murine C4. <i>Nature</i> , 1975, 258, 242-243.	27.8	101
28	Complement-Induced Release of Monocyte Chemotactic Protein-1 From Human Smooth Muscle Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 673-677.	2.4	93
29	Streptococcal Inhibitor of Complement Inhibits Two Additional Components of the Mucosal Innate Immune System: Secretory Leukocyte Proteinase Inhibitor and Lysozyme. <i>Infection and Immunity</i> , 2002, 70, 4908-4916.	2.2	87
30	Three rat monoclonal antibodies to human C3. <i>Immunology</i> , 1980, 41, 503-15.	4.4	82
31	Functional and antigenic similarities between a 94-kD protein of <i>Schistosoma mansoni</i> (SCIP-1) and human CD59.. <i>Journal of Experimental Medicine</i> , 1994, 179, 1625-1636.	8.5	71
32	The immunoglobulin nature of nephritic factor (NeF). <i>Clinical and Experimental Immunology</i> , 1978, 32, 12-24.	2.6	70
33	Glycosylation Governs the Binding of Antipeptide Antibodies to Regions of Hypervariable Amino Acid Sequence within Recombinant gp120 of Human Immunodeficiency Virus Type 1. <i>Journal of General Virology</i> , 1990, 71, 2889-2898.	2.9	69
34	Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1987, 30, 961-966.	6.7	68
35	Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.. <i>Journal of Clinical Investigation</i> , 1975, 55, 668-672.	8.2	64
36	Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics. <i>Current Pharmaceutical Design</i> , 2004, 10, 2891-2905.	1.9	64

#	ARTICLE	IF	CITATIONS
37	Resolution and analysis of native and activated properdin. <i>Biochemical Journal</i> , 1987, 243, 507-517.	3.7	63
38	The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins. <i>Immunology</i> , 2004, 111, 444-452.	4.4	63
39	Interaction between Host Complement and Mosquito-Midgut-Stage <i>Plasmodium berghei</i> . <i>Infection and Immunity</i> , 2001, 69, 5064-5071.	2.2	62
40	Preparing serum for functional complement assays. <i>Journal of Immunological Methods</i> , 2010, 352, 195-197.	1.4	62
41	The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation. <i>European Journal of Immunology</i> , 1988, 18, 1217-1222.	2.9	58
42	Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. <i>Clinical and Experimental Immunology</i> , 1987, 69, 501-7.	2.6	58
43	Neutrophil Fc γ 3 and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. <i>European Journal of Immunology</i> , 1997, 27, 2514-2523.	2.9	56
44	The purification of specific antibody as F(ab)2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. <i>Immunochemistry</i> , 1971, 8, 81-88.	1.2	54
45	Studies on the terminal stages of complement lysis. <i>Immunology</i> , 1973, 24, 135-45.	4.4	54
46	Complement-mediated lysis of liposomes produced by the reactive lysis procedure. <i>Immunology</i> , 1970, 19, 983-6.	4.4	54
47	Molecular basis of subtotal complement C6 deficiency. A carboxy-terminally truncated but functionally active C6. <i>Journal of Clinical Investigation</i> , 1995, 95, 1877-1883.	8.2	51
48	Complement and immunity to viruses. <i>Immunological Reviews</i> , 1997, 159, 69-77.	6.0	48
49	Low-dose recombinant properdin provides substantial protection against <i>Streptococcus pneumoniae</i> and <i>Neisseria meningitidis</i> infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5301-5306.	7.1	48
50	The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. <i>Clinical and Experimental Immunology</i> , 1968, 3, 447-55.	2.6	44
51	Lectin pathway effector enzyme mannan-binding lectin-associated serine protease 2 can activate native complement C3 in absence of C4 and/or C2. <i>FASEB Journal</i> , 2017, 31, 2210-2219.	0.5	43
52	Studies on antigenic competition. II. Abolition of antigenic competition by antibody against or tolerance to the dominant antigen: a model for antigenic competition. <i>Immunology</i> , 1972, 22, 185-97.	4.4	43
53	Statistical issues in first-in-man studies. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2007, 170, 517-579.	1.1	40
54	A systematic study of neutrophil degranulation and respiratory burst <i>in vitro</i> by defined immune complexes. <i>Clinical and Experimental Immunology</i> , 2008, 101, 507-514.	2.6	40

#	ARTICLE	IF	CITATIONS
55	The complement-inhibiting protein, Protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. <i>Clinical and Experimental Immunology</i> , 2008, 83, 251-256.	2.6	39
56	Lymphocytotropic Strains of HIV Type 1 When Complexed with Enhancing Antibodies Can Infect Macrophages via Fc γ RIII, Independently of CD4. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 343-352.	1.1	35
57	A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1994, 49, 272-280.	5.7	34
58	Bispecific antibody: a tool for diagnosis and treatment of disease. <i>Clinical and Experimental Immunology</i> , 2008, 79, 315-321.	2.6	34
59	Microbial subversion of the immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8461-8462.	7.1	33
60	Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. <i>Biochemical Journal</i> , 1988, 253, 667-675.	3.7	32
61	Attribution of the Various Inhibitory Actions of the Streptococcal Inhibitor of Complement (SIC) to Regions within the Molecule. <i>Journal of Biological Chemistry</i> , 2005, 280, 20120-20125.	3.4	32
62	The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens. <i>Journal of General Virology</i> , 1990, 71, 1975-1983.	2.9	31
63	Complement before molecular biology. <i>Molecular Immunology</i> , 2006, 43, 496-508.	2.2	31
64	Taking Complement to the Clinic "has the Time Finally Come?". <i>Scandinavian Journal of Immunology</i> , 2009, 69, 471-478.	2.7	31
65	Sequence-specific. <i>Protein Science</i> , 1993, 2, 2015-2027.	7.6	30
66	CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients. <i>Clinical and Experimental Immunology</i> , 1996, 105, 497-503.	2.6	30
67	Looking back on the alternative complement pathway. <i>Immunobiology</i> , 2018, 223, 519-523.	1.9	30
68	Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. <i>Clinical and Experimental Immunology</i> , 2008, 87, 415-421.	2.6	29
69	Experimental confirmation of the C3 tickover hypothesis by studies with an Ab (S77) that inhibits tickover in whole serum. <i>FASEB Journal</i> , 2018, 32, 123-129.	0.5	29
70	Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle <i>in vitro</i> . <i>Clinical and Experimental Immunology</i> , 2015, 181, 314-322.	2.6	28
71	An attempt to characterize the lupus erythematosus cell antigen. <i>Immunology</i> , 1961, 4, 153-63.	4.4	28
72	Lymphosarcoma, Cold Urticaria, IgG ₁ Monoclonal Cryoglobulin and Complement Abnormalities. <i>Scandinavian Journal of Haematology</i> , 1975, 15, 22-26.	0.0	27

#	ARTICLE	IF	CITATIONS
73	How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion. <i>Immunology</i> , 1996, 88, 407-411.	4.4	25
74	Lupus and desoxyribonuclease. <i>Lupus</i> , 2003, 12, 202-206.	1.6	25
75	An anti-peptide antibody that recognizes a neo-antigen in the CR1 stump remaining on erythrocytes after proteolysis. <i>Clinical and Experimental Immunology</i> , 2008, 87, 144-149.	2.6	24
76	Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. <i>Clinical and Experimental Immunology</i> , 1985, 61, 1-8.	2.6	21
77	Mechanisms of oligodendrocyte interaction with normal human serum - defining the role of complement. <i>Journal of the Neurological Sciences</i> , 1992, 108, 65-72.	0.6	20
78	Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope. <i>Journal of General Virology</i> , 1993, 74, 2609-2617.	2.9	20
79	The profiles of interleukin (IL)-2, IL-6, and interferon-gamma production by peripheral blood mononuclear cells from house-dust-mite-allergic patients: a role for IL-6 in allergic disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1994, 49, 751-759.	5.7	20
80	Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities. <i>Microbes and Infection</i> , 2007, 9, 300-307.	1.9	20
81	Study of the in vitro activation of the complement alternative pathway by <i>Echinococcus granulosus</i> hydatid cyst fluid. <i>Parasite Immunology</i> , 1995, 17, 245-251.	1.5	18
82	Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. <i>Journal of General Virology</i> , 1992, 73, 1099-1106.	2.9	17
83	Subversion of the innate immune response by micro-organisms. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 8ii-12.	0.9	16
84	The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 1179-1189.	0.5	16
85	The in vivo destruction of antigen-a tool for probing and modulating an autoimmune response. <i>Clinical and Experimental Immunology</i> , 1996, 106, 187-189.	2.6	15
86	Determination of CD59 protein in normal human serum by enzyme immunoassay, using octyl-glucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex. <i>Immunology Letters</i> , 2003, 90, 209-213.	2.5	15
87	Herpes virus saimiri CD59 - baculovirus expression and characterisation of complement inhibitory activity. <i>Biochemical Society Transactions</i> , 1997, 25, 354S-354S.	3.4	14
88	Neutrophil lactoferrin release induced by IgA immune complexes differed from that induced by cross-linking of Fc γ receptors (Fc γ R) with a monoclonal antibody, MIP8a. <i>Clinical and Experimental Immunology</i> , 2000, 121, 106-111.	2.6	14
89	The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006, 8, R68.	3.5	14
90	Neutrophil lactoferrin release induced by IgA immune complexes can be mediated either by Fc alpha receptors or by complement receptors through different pathways. <i>Journal of Immunology</i> , 1996, 156, 2599-606.	0.8	14

#	ARTICLE	IF	CITATIONS
91	An estimate of some molecular parameters of bovine conglutinin. <i>Immunochemistry</i> , 1964, 1, 37-41.	1.2	13
92	Health risks of genetically modified foods. <i>Lancet</i> , The, 1999, 354, 69.	13.7	13
93	Consent and confidentiality—where are the limits? An introduction. <i>Journal of Medical Ethics</i> , 2003, 29, 2-3.	1.8	13
94	The Grandmother Effect. <i>Gerontology</i> , 2011, 57, 375-377.	2.8	13
95	Complement component C6 and C7 haplotypes associated with deficiencies of C6. <i>Annals of Human Genetics</i> , 1995, 59, 183-195.	0.8	12
96	Public Health and Bioethics. <i>Journal of Medicine and Philosophy</i> , 1998, 23, 297-302.	0.8	12
97	Microbial immunology: A new mechanism for immune subversion. <i>Current Biology</i> , 1998, 8, R99-R101.	3.9	11
98	Anti-DNA antibodies in the urine of lupus nephritis patients. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 1418-1424.	0.7	11
99	Antibodies raised to short synthetic peptides with sequences derived from HIV-1 SF2 gp120 can both neutralize and enhance HIV-1 SF13: A later variant isolated from the same host. <i>Journal of Medical Virology</i> , 2001, 64, 207-216.	5.0	11
100	C7 M/N protein polymorphism typing applied to inherited deficiencies of human complement proteins C6 and C7. <i>Clinical and Experimental Immunology</i> , 2008, 89, 485-489.	2.6	11
101	Construction, expression and functional analysis of a glycolipid-linked form of CR1. <i>European Journal of Immunology</i> , 1993, 23, 2346-2352.	2.9	10
102	Stem cell research—why is it regarded as a threat?. <i>EMBO Reports</i> , 2001, 2, 165-168.	4.5	10
103	Inhibition of antimicrobial peptides by group A streptococci: SIC and DRS. <i>Biochemical Society Transactions</i> , 2006, 34, 273.	3.4	10
104	Crystal-ball gazing—the future of immunological research viewed from the cutting edge. <i>Clinical and Experimental Immunology</i> , 2006, 147, 061120065600010-???	2.6	10
105	Comparison of C1q-receptors on rat microglia and peritoneal macrophages. <i>Journal of Neuroimmunology</i> , 1999, 94, 74-81.	2.3	9
106	Cytostasis of different tumours by a murine PPD-reactive CD4+ T lymphocyte clone is mediated by interferon-gamma and tumour necrosis factor alone or synergistically. <i>Clinical and Experimental Immunology</i> , 2008, 82, 208-213.	2.6	9
107	Difficulties in the ascertainment of C9 deficiency: lessons to be drawn from a compound heterozygote C9-deficient subject. <i>Clinical and Experimental Immunology</i> , 1997, 108, 500-506.	2.6	8
108	C6 haplotypes: associations of a Dde I site polymorphism to complement deficiency genes and the Msp I restriction fragment length polymorphism (RFLP). <i>Clinical and Experimental Immunology</i> , 2008, 95, 351-356.	2.6	8

#	ARTICLE	IF	CITATIONS
109	Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype. Clinical and Experimental Immunology, 2015, 183, 150-156.	2.6	8
110	Neuronal protection of oligodendrocytes from antibody-independent complement lysis. NeuroReport, 1998, 9, 927-932.	1.2	7
111	Genetic and Cultural Evolution: From Fossils to Proteins, and from Behaviour to Ethics. European Review, 2010, 18, 297-309.	0.7	7
112	A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates. Clinical and Experimental Immunology, 2008, 82, 200-207.	2.6	6
113	GM food debate. Lancet, The, 1999, 354, 1726.	13.7	4
114	Anti-infective antibodiesâ€”Reviving an old paradigm. Vaccine, 2009, 27, G33-G37.	3.8	4
115	Religionâ€”An evolutionary adaptation. FASEB Journal, 2010, 24, 1301-1307.	0.5	4
116	Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK. Lancet, The, 2011, 377, 1149.	13.7	4
117	Complement in IgA immune-complex-induced neutrophil activation. Biochemical Society Transactions, 1997, 25, 462-466.	3.4	3
118	A NOVEL HUMAN COMPLEMENT COMPONENT C7 PHENOTYPE DETECTED IN SOUTH AFRICA AND PROPOSED DESIGNATION OF THE ALLELE AS C7*10. International Journal of Immunogenetics, 1994, 21, 181-187.	1.2	2
119	Ethics Evolve. European Review, 2013, 21, S109-S113.	0.7	2
120	Introduction. Seminars in Immunopathology, 1994, 15, 303-306.	4.0	1
121	The risk to the United Kingdom population of zinc cadmium sulfide dispersion by the Ministry of Defence during the "cold war". Occupational and Environmental Medicine, 2002, 59, 13-17.	2.8	1
122	Stem cell therapy: medical advance or moral challenge?. Comptes Rendus - Biologies, 2002, 325, 1049-1051.	0.2	1
123	The complement system in renal diseases. , 2006, , 1-18.		1
124	Peptide inhibitors of C3 breakdown. Clinical and Experimental Immunology, 2008, 79, 454-458.	2.6	1
125	Robert Royston Amos (Robin) Coombs. 9 January 1921 â€” 25 January 2006. Biographical Memoirs of Fellows of the Royal Society, 2009, 55, 45-58.	0.1	1
126	A More Radical Solution. Reviews on Recent Clinical Trials, 2015, 10, 25-27.	0.8	1

#	ARTICLE	IF	CITATIONS
127	It's what not where you publish that matters. <i>Astronomy and Geophysics</i> , 1998, 39, 3.9-3.9.	0.2	0
128	Henry Kunkel. <i>Lupus</i> , 2003, 12, 200-201.	1.6	0
129	Traditional passive immune therapy for emerging Ebola infection. <i>Emerging Microbes and Infections</i> , 2014, 3, 81-2.	6.5	0
130	Editorial (Thematic Issue: The Urgent Need to Reform the Present System of Medicinesâ€™ Regulation). <i>Reviews on Recent Clinical Trials</i> , 2015, 10, 2-4.	0.8	0
131	John Gordonâ€™A greatly undervalued complement pioneer. <i>Immunobiology</i> , 2018, 223, 524-525.	1.9	0
132	The Two Cultures at Cambridge. <i>European Review</i> , 2019, 27, 46-53.	0.7	0
133	An open letter to the health secretary: how to really save money on the NHS. <i>BMJ: British Medical Journal</i> , 2010, 341, c5618-c5618.	2.3	0
134	Britain's Academy of Medical Sciences has been busy in recent months. <i>BMJ: British Medical Journal</i> , 1999, 318, 1624-1624.	2.3	0